Search form
Search
Login
Subscribe
Home
Country Intelligence
Industry Directory
Offsets / IC
Tenders
Australia
(13/week)
Haiti
(0/week)
Guyana
(0/week)
Honduras
(0/week)
Guatemala
(0/week)
View all
(13/week)
News
United States
(421/week)
Manufacturing
(319/week)
Technology
(320/week)
Energy
(213/week)
Other Manufacturing
(264/week)
Events
About us
Who we are
Our People
Partners
Contact us
LinkedIn
Login
Twitter
Register
Home
News
Eczema Area and Severity Index
Jun 18, 2020
RINVOQ(TM) (upadacitinib) Monotherapy Shows Improvement in Skin Clearance and Itch in First Phase 3 Study for Atopic Dermatitis
May 26, 2020
Arena Completes Full Enrollment of Etrasimod Phase 2 ADVISE Trial for Atopic Dermatitis, Provides Program Updates
Oct 28, 2019
Arena Pharmaceuticals Announces First Subject Dosed in ADVISE Phase 2 Trial Evaluating Etrasimod in Atopic Dermatitis
Oct 03, 2018
DS Biopharma Announces Positive Top-line Phase 2b Trial Results for Ds107 As a Topical Treatment for Mild to Moderate Atopic Dermatitis
Sep 13, 2018
AbbVie Presents Upadacitinib Longer-Term (32-Week) and Patient-Reported Outcomes Data from Phase 2b Atopic Dermatitis Study at 27th European Academy of Dermatology and Venereology (EADV) Congress
Jul 10, 2018
Realm Therapeutics Announces Publication of Pre-Clinical Study Demonstrating Comparable Activity of PR022 and Topical Tofacitinib in the Treatment of Atopic Dermatitis
May 24, 2018
Realm Therapeutics Completes Enrollment in Phase 2 Study of PR022 for Atopic Dermatitis
May 17, 2018
Glenmark Pharmaceuticals Announces Oral Presentation of New Data on GBR 830, an Investigational, Anti-OX40 Monoclonal Antibody, at the International Investigative Dermatology Meeting
Apr 16, 2018
Glenmark Pharmaceuticals Announces Initiation of a Phase 2b Trial of GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody for the Treatment of Moderate-to-Severe Atopic Dermatitis
Feb 17, 2018
AbbVie Presents New Late-Breaking Phase 2b Data on Upadacitinib in Atopic Dermatitis at the 2018 American Academy of Dermatology Annual Meeting
Feb 16, 2018
Glenmark Pharmaceuticals Presents New Data on GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody for the Treatment of Moderate-to-Severe Atopic Dermatitis at the 2018 American Academy of Dermatology Annual Meeting
Feb 15, 2018
Realm Therapeutics Highlights Strong 2017 Performance and Outlines 2018 Milestones
Dec 05, 2017
Realm Therapeutics Announces First Patient Dosed in Phase 2 Study of PR022 for the Treatment of Atopic Dermatitis
Dec 04, 2017
Health Canada approves Dupixent(TM), the first targeted treatment for adults with moderate-to-severe atopic dermatitis
Sep 07, 2017
AbbVie's Upadacitinib (ABT-494) Meets Primary Endpoint in Phase 2b Study in Atopic Dermatitis
Sep 06, 2017
Medimetriks Announces Phase 2 Study Results Demonstrating Early Itch Relief for Topical PDE4 Inhibitor MM36 in Patients with Atopic Dermatitis
Jul 31, 2017
Glenmark Pharmaceuticals Reports Positive Data in a Phase 2a Study of GBR 830 for the Treatment of Patients with Atopic Dermatitis
Latest News
Mar 29, 2024
Universal Display Corporation to Deliver Keynote Address and Sponsor ICDT 2024
Mar 29, 2024
Cepton, Inc. Reports Fourth Quarter and Full Year 2023 Results
Mar 29, 2024
Ascent Industries Reports Fourth Quarter and Full Year 2023 Results
Mar 29, 2024
Surf Air Mobility Reports Financial Results for Fourth Quarter and Full Year Ended December 31, 2023
Mar 29, 2024
Planet Reports Financial Results for Fourth Quarter and Full Fiscal Year 2024
Mar 29, 2024
Fastenal Releases 2024 Environmental, Social, and Governance (ESG) Report
Mar 29, 2024
Danimer Scientific Announces Fourth Quarter and Full Year 2023 Results
Mar 29, 2024
CVD Equipment Corporation Reports Fourth Quarter and Fiscal Year 2023 Financial Results
View all News
Agenda
17
June
France
Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024, 17 - 21 June 2024, Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024 There can be no sustainable world without peace and security. Founded in 1967, the exhibition...
21
May
Paris Marriott Rive Gauche & Conference Center
Future Artillery, 21-23 May 2024, Paris Marriott Rive Gauche & Conference Center, France
DELIVERING FIRES IN THE MULTI-DOMAIN BATTLESPACE As artillery reasserts itself as the ‘King of Battlefield’ in the wake...
21
May
United Arab Emirates
ADNEC (Abu Dhabi National Exhibition Centre), Abu Dhabi, Al Khaleej Al Arabi St - Al Rawdah - Al Ma'arid - Abu Dhabi, UAE
ISNR Abu Dhabi 2024, 21-23 May 2024, ADNEC (Abu Dhabi National Exhibition Centre), Abu Dhabi, Al Khaleej Al Arabi St - Al Rawdah - Al Ma'arid - Abu Dhabi, UAE
ISNR ACCELERATING TRANSFORMATION IN THE NATIONAL SECURITY ECOSYSTEM ISNR Abu Dhabi is the region’s most trusted...
View All Events